News & Updates

Updates, press releases, and news on our work on GB-13.

Targepeutics Joins the ‘Help and Hope Happens Here’ Podcast

Sil Lutkewitte, Chief Executive Officer, and Randy Schrecengost, Chief Scientific Officer, at Targepeutics had the opportunity to join Mark Levine as guests on his podcast ‘ Help and Hope Happen…

Read More

Targepeutics Presenting Data at 29th Annual Meeting of the Society of Neuro-Oncology (SNO)

Targepeutics is presenting the latest preclinical data related to ongoing development of the novel immunotoxin, GB13, for the treatment of GBM.  This data will presented as a poster presentation during…

Read More

Collaborative Grant with PSU Department of Neurosurgery Awarded

Penn State University College of Medicine, Department of Neurosurgery and Targepeutics are pleased to announce that they have been awarded a W.W. Smith Charitable Trust Medical grant.  This grant will…

Read More

Targepeutics to Present Latest DMG and GBM Data at Society for NeuroOncology Annual Meeting

Targepeutics is presenting the latest efficacy data related to treatment of GBM and DMG tumors with the novel immunotoxin, GB13. This data is presented as a poster presentation during the…

Read More

Targepeutics Announces Phase I SBIR Grant to Support GB-13 Development

Targepeutics announces a Phase I Small Business Innovation Research (SBIR) grant awarded to Dr Randy Schrecengost as Primary Investigator to support preliminary data demonstrating that GB13 can specifically target IL13Rα2-positive…

Read More

GB13 Clinical Trial Presented at International Conference

A poster presentation, entitled LOCO-REGIONAL INFUSION OF GB-13 (IL13.E13K-PE4E) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT HIGH-GRADE GLIOMA is presented at the SNO 2022 Annual Clinical Trials and Brain Metastases…

Read More